Showing 2981-2990 of 4263 results for "".
- FDA Approves BMS's Opdivo as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Diseasehttps://practicaldermatology.com/news/fda-approves-bmss-opdivo-as-adjuvant-therapy-in-patients-with-completely-resected-melanoma-with-lymph-node-involvement-or-metastatic-disease/2457941/The FDA has approved Bristol-Myers Squibb Company's Opdivo (nivolumab) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. The purpose of adjuvant therapy is to reduce t
- Microarray Skin Patch May Help Solve Antibiotic Resistance Crisishttps://practicaldermatology.com/news/microarray-skin-patch-may-help-solve-antibiotic-resistance-crisis/2457939/Skin microarray patches that administer drugs directly into the bloodstream through thousands of individual “microneedles” may help solve the antibiotic resistance crisis. “One of the biggest problems is that the huge majority of the drugs are taken orally. This me
- FDA Grants Extended Clearance of the Describe Patch for Tattoo Removalhttps://practicaldermatology.com/news/fda-grants-extended-clearance-of-the-describe-patch-for-tattoo-removal/2457960/Merz North America’s DESCRIBE® PFD Patch is now cleared by the Food and Drug Administration (FDA) for all commonly used lasers for tattoo removal. The new FDA clearance also extends the shelf life of the Patch from two years
- Long-Term Use of Lilly's Taltz Shows Efficacy Improvements in PsA for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitorshttps://practicaldermatology.com/news/long-term-use-of-lillys-taltz-shows-efficacy-improvements-in-psa-for-patients-with-prior-inadequate-response-or-intolerance-to-tnf-inhibitors/2457980/Patients with active psoriatic arthritis (PsA) treated with Taltz (ixekizumab), who were previously intolerant or had inadequate responses to TNF inhibitors, showed improvements in the signs and symptoms of PsA across treatment groups for up to 52 weeks, according to Eli Lilly and Company. Interi
- NRS Introduces New Standard Classification and Pathophysiology of Rosaceahttps://practicaldermatology.com/news/nrs-introduces-new-standard-classification-and-pathophysiology-of-rosacea/2457979/The National Rosacea Society (NRS) is introducing a new standard classification and pathophysiology of rosacea. The updated system appears in the Journal of the American Academy of Dermatology. Devel
- Study: PsO, RA Patients Prescribed Similar Drugs, But PsO Patients Face Higher Liver Disease Riskhttps://practicaldermatology.com/news/study-pso-ra-patients-prescribed-similar-drugs-yet-pso-patients-face-higher-liver-disease-risk/2457987/Compared to controls, patients with psoriasis (PsO) are at higher risk for serious liver disease than patients with rheumatoid arthritis, reports a in the Journal of Investigative Dermatology from researchers a
- Dermatomyositis Breakthrough? Drug reduces disease burden in patients with skin-predominant DMhttps://practicaldermatology.com/news/dermatomyositis-breakthrough-drug-reduces-disease-burden-in-patients-with-skin-predominant-dm/2457990/A new treatment for dermatomyositis (DM) may reduce the severity of the disease in patients whose DM was resistant to other therapies. As part of a randomized, double-blind study conducted at the Perelman School of Medicine at the University of Pennsyl
- Prospective Cosmetic Surgery Patients Often In The Dark About Financing Optionshttps://practicaldermatology.com/news/prospective-cosmetic-surgery-patients-in-the-dark-about-financing-options/2457994/Fully 76 percent of prospective patients are unaware of financing options for cosmetic procedures, yet almost two-thirds of them would be more likely to book if they were aware that financing was a viable option, according to a survey by
- Sun Dermatology Launches Absorica Tracker App to Help Patients Track Progresshttps://practicaldermatology.com/news/sun-dermatology-launches-absorica-tracker-app-to-help-patients-track-progress/2457999/Sun Pharma launched an Absorica Tracker App to help patients get the most out of their treatment. The easy-to-use interface is designed to help users to monitor their progress with Absorica (isotretinoin) treatment with features like medication and appointment reminders, monthly tips and checklis
- Medicaid Patients May Receive Less Timely Melanoma Surgeryhttps://practicaldermatology.com/news/medicaid-patients-may-receive-less-timely-melanoma-surgery/2458028/Delays in melanoma surgery may vary by insurance type, according to research in JAMA Dermatology. While Medicaid patients had the highest likelihood of delays, significant pro